k.redgrave
TL2 Member · Aachen, DE
Based in the EU. Tracks what is available and funded locally, and dates every claim.
Joined 6 June 2025 · last posted 14d · groups: regional-eu
96Posts here
2Topics
1Solutions
338Likes received
225Likes given
22Badges
149Days visited
1.6kPosts read
Stated areas
Recent activity
Full stream-
A critique that turned out to be unfair, retracted by its author Replied, post #30 · Evidence › Study critique · 14 Jul 2026 · 14 likes I would be cautious about generalising from the critique example above. It is a good example. It is one example.
-
Why we ask for units every single time, with three examples of what goes wrong Replied, post #114 · Start Here › How to Ask · 10 Jul 2026 · 0 likes A photograph of a vial is rarely useful and a photograph of a document usually is. Redact the identifiers before you post either.
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #118 · Practice › Reconstitution · 10 Jul 2026 · 25 likes I would keep 5 mg vial and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #56 · Analytics › Impurities & related substances · 7 Jul 2026 · 19 likes Related substances: compounds chemically related to the target peptide but not the target peptide itself. The standard method separates them and reports them as area…
-
Journal club: what we got wrong in an earlier session Replied, post #26 · Evidence › Journal club · 24 Jun 2026 · 10 likes Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.
-
Research-use-only status: what it means legally and practically Replied, post #59 · Compounds › Other compounds · 16 Jun 2026 · 4 likes Several compounds discussed here have no published human pharmacokinetics at all. That means half-life claims in circulation were derived from an animal model or from…
-
CJC-1295 with and without DAC: what the modification does Replied, post #85 · Compounds › Secretagogues & GH axis · 16 Jun 2026 · 0 likes Thank you — that answers what I came here to find out.
-
Transporting a vial for a weekend away — a second dataset Replied, post #79 · Practice › Storage & stability · 11 Jun 2026 · 7 likes Picking up post #76: that is the part I would want checked first. Checked the Transporting a vial claim against the primary source this morning. It survives, with a…
-
What steady state means for the decision to escalate Replied, post #11 · Practice › Dosing & titration · 9 Jun 2026 · 6 likes Noted, and thank you for writing it out rather than summarising it.
-
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? Replied, post #30 · Compounds › Repair & healing peptides · 8 Jun 2026 · 0 likes The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic…
-
Tracking a shortage from primary sources rather than rumour Replied, post #41 · Access › Shortages · 8 Jun 2026 · 6 likes Shortage predictions: regulators and suppliers issue shortage alerts before they become acute. Checking the regulatory website for shortages gives you advance notice.…
-
MS/MS sequence confirmation: what it costs and when it is worth it — what changed since Replied, post #33 · Analytics › Mass spectrometry · 1 Jun 2026 · 16 likes Coming back to post #31, because the follow-up matters more than the original answer. Tandem mass spectrometry with fragmentation gives sequence information that intact…